Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Metriopharm AG has 5 pending office actions in Biotechnology & Pharmaceuticals. The docket is spread across 5 examiners and 4 art units, indicating distinct examiner relationships with some art-unit overlap.
SHIAO, REI TSANG is the busiest examiner, with 1 pending action. Counsel should track each examiner separately while using the shared art-unit structure to identify prosecution practices that may affect more than one matter.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001034 | COMPOUND FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | BAUER, NICOLA MARIA | 88d overdue |
| 18726854 | COMBINATION OF BUDESONIDE AND 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001034 | COMPOUND FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | BAUER, NICOLA MARIA | 88d overdue |
| 18255262 | LUMINOL FOR THE PROPHYLAXIS AND THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | NESTOR, DONNA MICHELLE | 42d overdue |
| 18726854 | COMBINATION OF BUDESONIDE AND 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | GONZALEZ, LUISALBERTO | — |
| 17913687 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR TREATMENT OF ACUTE LUNG INJURY | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1691 | 2 |
| 1624 | 1 |
| 1627 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850379 | COMBINATION OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AND A FUMARIC ACID ESTER | SHIAO, REI TSANG | 1691 | §103§112DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18726854 | COMBINATION OF BUDESONIDE AND 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | GONZALEZ, LUISALBERTO | 1624 | §103§112Other | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18255262 | LUMINOL FOR THE PROPHYLAXIS AND THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | NESTOR, DONNA MICHELLE | 1627 | §103DP | Non-Final OA | 42d overdue | Pending | May 31, 2023 |
| 18001034 | COMPOUND FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | BAUER, NICOLA MARIA | 1621 | §103§112 | Final Rejection | 88d overdue | Pending | Dec 07, 2022 |
| 17913687 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR TREATMENT OF ACUTE LUNG INJURY | LEE, ANDREW P | 1691 | §103 | Final Rejection | — | Pending | Sep 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMetriopharm AG has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Rei Tsang Shiao has the most, with 1 of Metriopharm AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
